The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary

Introduction. Triple-negative breast cancer (BC) is very aggressive form of breast malignancies with high levels of dissemination, frequent ecurrence and poor survival rate, as compared to other breast cancer subtypes.

Aim of the study – development and introduction of optimized treatment strategy of patients with triple-negative breast cancer into the clinical practice of City Clinical Oncological Dispensary.

Materials and methods. The study included 201 patients (21–90 years, mean age 52 years) who were treated in the first department
of St. Petersburg City Clinical Oncological Dispensary from 2005 to 2011. Stage IА–IIIC invasive breast cancer with triple-negative phenotype according to immunohistochemical study of the tumor material was verified in all the patients before beginning of the treatment. Standard chemotherapy by FAC, CMF and taxane-containing regimen was used as neoadjuvant chemotherapy. The degree of therapeutic pathomorphism was evaluated according to Miller-Payne (2003) classification, which was designed taking into account an overall survival rate of patients, depending on the degree of pathologic tumor regression.

Results. We performed evaluation of 3-year relapse-free survival, depending on the degree of pathomorphological regression and histological degree of malignancy. There is a clear dependence of the 3-year relapse-free survival on the degree of histological differentiation of the tumor. We noted an inverse correlation between high degree of histological malignancy with a short relapse-free period. The disease progressed in patients who have a high degree of histological malignancy.

Conclusion. The highest efficiency was achieved in patients receiving chemotherapy with the addition of taxanes. It is advantageous to include taxane-containing chemotherapy regimens in the treatment of patients with a high degree of histological malignancy.

1. Аксель Е. М. Заболеваемость злокачественными новообразованиями и смертность от них в Москве и Санкт-Петербурге в 2009 г. Вестник РОНЦ им. Н. Н. Блохина РАМН 2011;22(3 прил. 1):124–42. [Aksel E. M. The incidence of malignant tumors, and mortality from them in Moscow and St. Petersburg in 2009. Vestnik RONC im. N. N. Blohina RAMN = Bulletin of the Russian Cancer Research Center named after N. N. Blokhin, Russian Academy of Medical Sciences 2011;22(3 Suppl 1): 124–42. (In Russ.)].

2. Perou C. M., Srlie T., Eisen M. B. et al. Molecular portraits of human breast tumours. Nature 2011;406(6797):747–52. [Davydov M. I., Aksel E. M. The incidence of malignant tumors among population of Russia and CIS countries in 2004. Vestnik RONC im. N. N. Blohina RAMN = Bulletin of the Russian Cancer Research Center named after N. N. Blokhin, Russian Academy of Medical Sciences 2006;17(3 Suppl 1). 132 p. (In Russ.)].

3. Давыдов М. И., Аксель Е. М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2004 г. Вестник РОНЦ им. Н. Н. Блохина РАМН 2006;17(3 прил. 1). 132 с. [Davydov M. I., Aksel E. M. Statistics of malignancies in Russia and CIS countries in 2007. Vestnik RONC im. N. N. Blohina RAMN = Bulletin of the Russian Cancer Research Center named after N. N. Blokhin, Russian Academy

4. of Medical Sciences 2009; 20(3 Suppl 1). 158. (In Russ.)].

5. Liedtke C., Mazouni C., Hess K. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative. breast cancer. J Clin Oncol 2008;2:1275–81.

6. Carey L., Perou C., Livasy C. et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006;295:2492–502.

7. Демидов С. М., Дорофеев А. В., Сазонов С. В. Некоторые закономерности экспрессии Estrogen, Progesterone Receptor и KI-67 на опухолевых клетках карциномы молочной железы. Уральский медицинский журнал 2010;(12):68–71. [Demidov S. M., Dorofeev A. V., Sazonov S. V. Some patterns of Estrogen, Progesterone Receptor and KI-67 expression on tumor cells of breast carcinoma. Uralskiy meditsinskiy zhurnal = Ural Journal of Medicine 2010;(12):68–71. (In Russ.)].

8. Кулигина Е. Ш. Эпидемиологические и молекулярные аспекты рака молочной железы. Практическая онкология 2010;11 (4): 203–16. [Kuligina E. Sh. Epidemiological and

9. molecular aspects of breast cancer. 2010 (In Russ.)].

10. Лимарева С. В. Таксаны в адъювантной и неоадъювантной терапии рака молочной железы. Опухоли женской репродуктивной системы 2010;(4):15–23. [Limareva S. V. Adjuvant and neoadjuvant therapy of breast cancer with taxanes. Opuholi zhenskoy reproduktivnoy sistemy = Female reproductive system tumors 2010;(4):15–23. (In Russ.)].

11. Литвяков Н. В., Слонимская Е. М., Гарбуков Е. Ю. Связь безметастатической выживаемости больных раком молочной железы и вектора изменения экспрессии генов множественной лекарственной устойчивости в опухоли при проведении неоадъювантной химиотерапии. Вопросы онкологии 2013;(3):334–40. [Litvyakov N. V., Slonimskaya E. M., Garbukov E. Yu. Association of metastasis-free survival in patients with breast cancer and changes in expression vector of multidrug resistance gene in tumors during neoadjuvant chemotherapy. Voprosyi onkologii = Questions of Oncology 2013; (3):334–40. (In Russ.)].

12. Манихас А. Г., Бабешкин Р. Н. Современный взгляд на проблему трижды негативного и базальноподобного рака молочной железы. Уральский медицинский журнал 2014;(2):78–80. [Manikhas A. G., Babeshkin R. N. Modern view on the problem of triple-negative and basal cell-like breast cancer. Uralskiy meditsinskiy zhurnal = Ural Journal of Medicine 2014;(2): 78–80. (In Russ.)].

13. Мерабишвили В. М. Наблюдаемая и относительная выживаемость онкологических больных (популяционное исследование). Российский онкологический журнал 2012; (3):25–9. [Merabishvili V. M. Observed and relative survival of cancer patients (population study). Rossiyskiy onkologicheskiy zhurnal = Russian Journal of Oncology 2012;(3):25–9. (In Russ.)].

14. Мурзина Ю. А., Демидов С. М., Демидов Д. А., Ирих Т. О. Гормонотерапия – как метод лечения рака молочной железы у пациенток старше 70 лет. Уральский медицинский журнал 2015;(7):34–8. [Murzina Yu. A., Demidov S. M., Demidov D. A., Irih T. O. Hormone therapy as a method of breast cancer treatment in patients over 70 years. Uralskiy meditsinskiy zhurnal = Ural Journal of Medicine 2015;(7):34–8. (In Russ.)].

15. Поддубная И. В., Карселадзе Д. А. «Тройной негативный» рак молочной железы. Вестник РОНЦ им. Н. Н. Блохина РАМН 2009;20(3):12–9. [Poddubnaya I. V., Karseladze D. A. «Triple-negative» breast cancer. Vestnik RONC im. N. N. Blohina RAMN = Bulletin of the Russian Cancer Research Center named after N. N. Blokhin, Russian Academy of Medical Sciences 2009;20(3):12–9.(In Russ.)].

16. Поддубная И. В., Карселадзе А. И., Кулевич Е. Е. Морфология тройного негативного рака молочной железы. Архив патологии 2010;72(2):8–12. [Poddubnaya I. V., Karseladze A. I., Kulevich E. E. Morphology of triple-negative breast cancer. Arkhiv patologii = Archives of pathology 2010;72(2):8–12.(In Russ.)].

17. Поддубная И. В. Клиническая характеристика тройного негативного рака молочной железы. Вестник РОНЦ им. Н. Н. Блохина РАМН 2010;22(1):71–6. [Poddubnaya I. V. Clinical characteristics of triple-negative breast cancer. Vestnik RONC im. N. N. Blohina RAMN = Bulletin of the Russian Cancer Research Center named after N. N. Blokhin, Russian Academy of Medical Sciences 2010;22(1):71–6. (In Russ.)].

18. Портной С. М. Лечение местно-распространенного рака молочной железы. Сибирский онкологический журнал 2008; (2 прил.): 14–22. [Portnoy S. M. Treatment of locally advanced breast cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2008;(Suppl 2):14–22. (In Russ.)].

19. Семиглазов В. Ф. Основные результаты клинических исследований в онкологии в 2009 году. Фарматека 2010;(6):16–20. [Semiglazov V. F. Main results of clinical studies in oncology in 2009. Farmateka = Pharmateca 2010;(6):16–20. (In Russ.)].

20. Семиглазов В. Ф., Манихас А. Г., Семиглазов В. В. и др. Рак молочной железы. Химиотерапия и таргетная терапия. М.: МЕДпресс-информ, 2012. 360 с. [Semiglazov V. F., Manikhas A. G., Semiglazov V. V. et al. Breast Cancer. Chemotherapy and targeted therapy. M.: MEDpress-inform, 2012. 360 p. (In Russ.)].

21. Семиглазов В. Ф., Семиглазов В. В., Дашян Г. А. и др. Лечение «трижды негативного» рака молочной железы. Фарматека 2009;(18):16–20. [Semiglazov V. F., Semiglazov V. V., Dashyan G. A. et al. Treatment of «triple-negative» breast cancer. Farmateka = Pharmateca 2009;(18):16–20. (In Russ.)].

22. Bidard F. C., Conforti R., Boulet T. et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 «triple-negative» breast cancers. Ann Oncol 2007;18(7):1285–6.

23. Семиглазов В. Ф., Семиглазов В. В., Палтуев Р. М. Неоадъювантное лечение рака молочной железы. Опухоли женской репродуктивной системы 2014;2:30–6. [Semiglazov V. F., Semiglazov V. V., Paltuev R. M. Neoadjuvant treatment of breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Female reproductive system tumors 2014; (2):30–6. (In Russ.)].

24. Grabau D. A., Thropse S. M., Knoop A. et al. Immunohistochemical assesment of oestrogen and progesterone receptors: correlations with the DCC method and clinical outcome in primary breast cancer patients. The Breast 2000;9:208–17.

25. Тюляндин С. А., Стенина M. Б., Фролова М. А. Тройной негативный рак молочной железы. Практическая онкология 2010;11(4): 247–52. [Tjulyandin S. A., Stenina M. B., Frolova M. A. Triple-negative breast cancer. Prakticheskaya onkologiya = Practical oncology 2010;11(4):247–52. (In Russ.)].

26. Smith I., Heys S., Hutcheon A. et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J ClinOncol 2002;20(6):1456–66.

27. Реброва О. Ю. Статистический анализ медицинских данных: применение пакета прикладных программ: STATISTICA. М.: Медиа Сфера, 2006. 312 с. [Rebrova O. Yu. Statistical analysis of medical data: application of software package: STATISTICA. M.: Media Sphera, 2006. 312 p. (In Russ.)].

28. Ogston K. N., Miller I. D., Payne S. et al. A new histological grading system to assess response of breast carcinomas to primary chemotherapy: prognostic significance and survival. Breast 2003;12:320–7.

29. Elston C. W., Ellis I. O. Assessment of histological grade. In: Elston, C. W. and Ellis, I. O. (eds.). The breast. Vol. 13. Churchill Livingstone, Edinburgh; New York, 1998. Pp. 356–384.

30. Elston C.W., Ellis I. O., Pinder S. E. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol 1999;31:209–23.

31. Birnbaum D., Bertucci F, Ginestier C. et al. Basal and luminal breast cancers: basic or luminous. Int J Oncol 2004;25(2):249–58.

32. Carey L. A. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2010;15 Suppl 5:49–56. doi: 10.1634 / theoncologist. 2010-S5–49.

33. Bauer K., Brown M., Cress R. et al. Descriptive analysis of estrogen receptor (ER) – negative, progesterone receptor (PR) – negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 2007;109:1721–8.